Capmatinib, a selective MET inhibitor which was approved by the Food and Drug Administration (FDA) in 2020, has shown activity in malignancies with MET activation including the advanced NSCLC [6, 7]. This evidence concerns the gene MET and non-small cell lung carcinoma.